CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题：Therapeutic Potential of Innate Lymphoid Cells for Multiple Myeloma Therapy.
Therapeutic Potential of Innate Lymphoid Cells for Multiple Myeloma Therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
先天淋巴样细胞（ILC）是一类近期鉴定的淋巴细胞样细胞，缺乏特异性抗原受体，属于先天免疫系统。它们在组织稳态中发挥关键作用，并能调节炎症和肿瘤过程。对环境刺激作出反应时，ILC会改变表型和功能，并影响微环境中其他细胞的活性。ILC功能障碍可导致多种疾病，包括癌症。ILC可分为三个亚组：第1组包括NK细胞和ILC1；第2组仅包括ILC2；第3组包括淋巴组织诱导细胞（LTi）和ILC3。第1组ILC主要发挥抗肿瘤作用，而第2组和第3组ILC则具有促肿瘤特性。越来越多临床前和临床数据支持ILC参与多发性骨髓瘤（MM）发病机制。因此，靶向ILC可能具有临床获益。本文综述现有关于ILC在MM免疫学及治疗中作用的数据。
Innate lymphoid cells (ILCs) are a recently identified family of lymphocyte-like cells lacking a specific antigen receptor. They are part of the innate immune system. They play a key role in tissue homeostasis and also control inflammatory and neoplastic processes. In response to environmental stimuli, ILCs change their phenotype and functions, and influence the activity of other cells in the microenvironment.
ILC dysfunction can lead to a wide variety of diseases, including cancer. ILC can be divided into three subgroups: ILC Group 1, comprising NK cells and ILC1; Group 2, including ILC2 alone; and Group 3, containing Lymphoid Tissue inducers (LTi) and ILC3 cells. While Group 1 ILCs mainly exert antitumour activity, Group 2 and Group 3 ILCs are protumorigenic in nature. A growing body of preclinical and clinical data support the role of ILCs in the pathogenesis of multiple myeloma (MM).
Therefore, targeting ILCs may be of clinical benefit. In this manuscript, we review the available data on the role of ILCs in MM immunology and therapy.
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。
